Journal
Rare Tumors
Publication Date
2021
Volume
13
Issue
1
First Page
20363613211052498
Document Type
Open Access Publication
DOI
10.1177/20363613211052498
Rights and Permissions
Van Tine B, Weiss M, Hirbe A, Oppelt P, Abaricia S, Trinkaus K, Luo J, Berry S, Ruff T, Callahan C, Toensikoetter J, Ley J, Siegel M, Dehdashti F, Siegel B, Adkins D. Phase II study of dacarbazine given with modern prophylactic anti-emetics and growth factor support to patients with metastatic, resistant soft tissue, and bone sarcoma. Rare Tumors 2021 January 1. doi: 10.1177/20363613211052498. https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Recommended Citation
Van Tine, Brian; Weiss, Mia; Hirbe, Angela; Oppelt, Peter; Abaricia, Sarah; Trinkaus, Kathryn; Luo, Jingqin; Berry, Shellie; Ruff, Tyler; Callahan, Cheryl; Toensikoetter, Jacqui; Ley, Jessica; Siegel, Marilyn; Dehdashti, Farrokh; Siegel, Barry; and Adkins, Douglas, "Phase II study of dacarbazine given with modern prophylactic anti-emetics and growth factor support to patients with metastatic, resistant soft tissue, and bone sarcoma." Rare Tumors. 13, 1. 20363613211052498 (2021).
https://digitalcommons.wustl.edu/open_access_pubs/11053
